1887

Abstract

The liver-expressed pattern recognition receptors mannose-binding lectin (MBL), ficolin-2 and ficolin-3 contribute to the innate immune response by activating complement. Binding of soluble ficolin-2 to viral pathogens can directly neutralize virus entry. We observed that the human hepatoma cell line HuH7.5, which is routinely used for the study of hepatotropic viruses, is deficient in expression of MBL, ficolin-2 and ficolin-3. We generated a cell line that expressed and secreted ficolin-2. This cell line (HuH7.5 [FCN2]) was more resistant to infection with hepatitis C virus (HCV), ebolavirus and vesicular stomatitis virus, but surprisingly was more susceptible to infection with rabies virus. Cell-to-cell spread of HCV was also inhibited in ficolin-2 expressing cells. This illustrates that ficolin-2 expression in hepatocytes contributes to innate resistance to virus infection, but some viruses might utilize ficolin-2 to facilitate entry.

Keyword(s): entry , ficolin-2 , innate immunity , lectin and virus
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000935
2019-04-01
2019-10-19
Loading full text...

Full text loading...

References

  1. Thomson AW, Knolle PA. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 2010;10:753–766 [CrossRef]
    [Google Scholar]
  2. Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161–176 [CrossRef]
    [Google Scholar]
  3. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35–S50 [CrossRef]
    [Google Scholar]
  4. Cao X, Ding Q, Lu J, Tao W, Huang B et al. MDA5 plays a critical role in interferon response during hepatitis C virus infection. J Hepatol 2015;62:771–778 [CrossRef]
    [Google Scholar]
  5. Liang Y, Cao X, Ding Q, Zhao Y, He Z et al. Hepatitis C virus NS4B induces the degradation of TRIF to inhibit TLR3-mediated interferon signaling pathway. PLoS Pathog 2018;14:e1007075 [CrossRef]
    [Google Scholar]
  6. Tarr AW, Urbanowicz RA, Ball JK. The role of humoral innate immunity in hepatitis C virus infection. Viruses 2012;4:1–27 [CrossRef]
    [Google Scholar]
  7. Fuchs A, Pinto AK, Schwaeble WJ, Diamond MS. The lectin pathway of complement activation contributes to protection from West Nile virus infection. Virology 2011;412:101–109 [CrossRef]
    [Google Scholar]
  8. Brown KS, Keogh MJ, Owsianka AM, Adair R, Patel AH et al. Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. Protein Cell 2010;1:664–674 [CrossRef]
    [Google Scholar]
  9. Chang WC, Hartshorn KL, White MR, Moyo P, Michelow IC et al. Recombinant chimeric lectins consisting of mannose-binding lectin and L-ficolin are potent inhibitors of influenza A virus compared with mannose-binding lectin. Biochem Pharmacol 2011;81:388–395 [CrossRef]
    [Google Scholar]
  10. Fuchs A, Lin TY, Beasley DW, Stover CM, Schwaeble WJ et al. Direct complement restriction of flavivirus infection requires glycan recognition by mannose-binding lectin. Cell Host Microbe 2010;8:186–195 [CrossRef]
    [Google Scholar]
  11. Hamed MR, Brown RJ, Zothner C, Urbanowicz RA, Mason CP et al. Recombinant human L-ficolin directly neutralizes hepatitis C virus entry. J Innate Immun 2014;6:676–684 [CrossRef]
    [Google Scholar]
  12. Michelow IC, Dong M, Mungall BA, Yantosca LM, Lear C et al. A novel L-ficolin/mannose-binding lectin chimeric molecule with enhanced activity against Ebola virus. J Biol Chem 2010;285:24729–24739 [CrossRef]
    [Google Scholar]
  13. Pan Q, Chen H, Wang F, Jeza VT, Hou W et al. L-ficolin binds to the glycoproteins hemagglutinin and neuraminidase and inhibits influenza A virus infection both in vitro and in vivo. J Innate Immun 2012;4:312–324 [CrossRef]
    [Google Scholar]
  14. Zhao Y, Ren Y, Zhang X, Zhao P, Tao W et al. Ficolin-2 inhibits hepatitis C virus infection, whereas apolipoprotein E3 mediates viral immune escape. J Immunol 2014;193:783–796 [CrossRef]
    [Google Scholar]
  15. Brudner M, Karpel M, Lear C, Chen L, Yantosca LM et al. Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors. PLoS One 2013;8:e60838 [CrossRef]
    [Google Scholar]
  16. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 2003b;278:41624–41630 [CrossRef]
    [Google Scholar]
  17. Urbanowicz RA, McClure CP, King B, Mason CP, Ball JK et al. Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay. J Gen Virol 2016a;97:2265–2279 [CrossRef]
    [Google Scholar]
  18. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003a;197:633–642 [CrossRef]
    [Google Scholar]
  19. Urbanowicz RA, McClure CP, Brown RJ, Tsoleridis T, Persson MA et al. A diverse panel of hepatitis C virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance. J Virol 2015;90:3288–3301 [CrossRef]
    [Google Scholar]
  20. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 2002;76:13001–13014 [CrossRef]
    [Google Scholar]
  21. Hein E, Honoré C, Skjoedt MO, Munthe-Fog L, Hummelshøj T et al. Functional analysis of ficolin-3 mediated complement activation. PLoS One 2010;5:e15443 [CrossRef]
    [Google Scholar]
  22. Urbanowicz RA, McClure CP, Sakuntabhai A, Sall AA, Kobinger G et al. Human adaptation of Ebola virus during the West African outbreak. Cell 2016b;167:1079–1087 [CrossRef]
    [Google Scholar]
  23. McClure CP, Urbanowicz RA, King BJ, Cano-Crespo S, Tarr AW et al. Flexible and rapid construction of viral chimeras applied to hepatitis C virus. J Gen Virol 2016;97:2187–2193 [CrossRef]
    [Google Scholar]
  24. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791–796 [CrossRef]
    [Google Scholar]
  25. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL et al. Complete replication of hepatitis C virus in cell culture. Science (New York, NY) 2005;309:623–626 [CrossRef]
    [Google Scholar]
  26. Liu J, Ali MA, Shi Y, Zhao Y, Luo F et al. Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell Mol Immunol 2009;6:235–244 [CrossRef]
    [Google Scholar]
  27. Hummelshoj T, Munthe-Fog L, Madsen HO, Fujita T, Matsushita M et al. Polymorphisms in the FCN2 gene determine serum variation and function of ficolin-2. Hum Mol Genet 2005;14:1651–1658 [CrossRef]
    [Google Scholar]
  28. Hu YL, Luo FL, Fu JL, Chen TL, Wu SM et al. Early increased ficolin-2 concentrations are associated with severity of liver inflammation and efficacy of anti-viral therapy in chronic hepatitis C patients. Scand J Immunol 2013;77:144–150 [CrossRef]
    [Google Scholar]
  29. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P et al. Proteomics. Tissue-based map of the human proteome. Science (New York, NY) 2015;347:1260419 [CrossRef]
    [Google Scholar]
  30. Liu Y, Endo Y, Iwaki D, Nakata M, Matsushita M et al. Human M-ficolin is a secretory protein that activates the lectin complement pathway. J Immunol 2005;175:3150–3156 [CrossRef]
    [Google Scholar]
  31. Chen T, Hu Y, Ding Q, Yu J, Wang F et al. Serum ficolin-2 concentrations are significantly changed in patients with hepatitis B virus infection and liver diseases. Virol Sin 2015;30:249–260 [CrossRef]
    [Google Scholar]
  32. Luo F, Sun X, Wang Y, Wang Q, Wu Y et al. Ficolin-2 defends against virulent mycobacteria tuberculosis infection in vivo, and its insufficiency is associated with infection in humans. PLoS One 2013;8:e73859 [CrossRef]
    [Google Scholar]
  33. Mishra A, Antony JS, Sundaravadivel P, Tong HV, Meyer CG et al. Association of ficolin-2 serum levels and FCN2 genetic variants with Indian visceral leishmaniasis. PLoS One 2015;10:e0125940 [CrossRef]
    [Google Scholar]
  34. Nie J, Wu X, Ma J, Cao S, Huang W et al. Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system. Sci Rep 2017;7:42769 [CrossRef]
    [Google Scholar]
  35. Thoulouze MI, Lafage M, Montano-Hirose JA, Lafon M. Rabies virus infects mouse and human lymphocytes and induces apoptosis. J Virol 1997;71:7372–7380
    [Google Scholar]
  36. Favier AL, Gout E, Reynard O, Ferraris O, Kleman JP et al. Enhancement of Ebola virus infection via Ficolin-1 interaction with the mucin domain of GP glycoprotein. J Virol 2016;90:5256–5269 [CrossRef]
    [Google Scholar]
  37. Wojczyk BS, Takahashi N, Levy MT, Andrews DW, Abrams WR et al. N-glycosylation at one rabies virus glycoprotein sequon influences N-glycan processing at a distant sequon on the same molecule. Glycobiology 2005;15:655–666 [CrossRef]
    [Google Scholar]
  38. Klintworth A, Nolden T, Westhaus S, Rohrmann K, David S et al. Cationic amphiphilic drugs enhance entry of lentiviral particles pseudotyped with rabies virus glycoprotein into non-neuronal cells. Antiviral Res 2015;124:122–131 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000935
Loading
/content/journal/jmm/10.1099/jmm.0.000935
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error